Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Deciphering the Mechanisms Underpinning Breast Cancer Cell Intravasation and Extravasation in an in vitro Vascularized System

FY 2022-23

Summary
Breast cancer, the most diagnosed type of cancer worldwide, is the second leading cause of death in women. Metastatic breast cancer remains untreatable today, and crucial components in its development are still poorly understood. Two fundamental cellular processes during breast cancer metastasis are intravasation (movement of cells into the bloodstream) and extravasation (movement of cells from the bloodstream into the tissue). The mechanisms behind breast cancer cell intravasation and extravasation remain an undeciphered question, as animal studies face tremendous difficulties due to complex cellular interactions. Therefore, establishing an external vascularized system would allow us to continuously monitor cellular movement and shed light on this enigmatic process. Luo et al. 2019 journal article highlighted the importance of two proteins, DAAM1 and DAAM2, in cell motility. Luo showed that the downregulation of DAAM2 results in no cellular movements, and DAAM1 inhibits DAAM2-promoted cell motility. My underlying hypothesis is that loss of DAAM1 will promote intravasation and intravasation while loss of DAAM2 will hinder them. To test this hypothesis, I will investigate the capability of two breast cancer cell lines (one metastatic and one benign) to undergo intravasation and extravasation using an external vascularized system. I will first establish the malignant and benign vascularized breast cancer systems. And then perform loss of function (CRISPR) and overexpression screens (CRISPRa) in benign breast cancer cells that have undergone intravasation in these systems using FACS sorting, followed by next-generation sequencing of the guide RNA (which indicated gene deletion/overexpression).
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486379
Name
Guo Yaxin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Deciphering the Mechanisms Underpinning Breast Cancer Cell Intravasation and Extravasation in an in vitro Vascularized System
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cell Motility; Extravasation; In Vitro Vascularized System; Intravasation; Metastasis
Abstract
Breast cancer, the most diagnosed type of cancer worldwide, is the second leading cause of death in women. Metastatic breast cancer remains untreatable today, and crucial components in its development are still poorly understood. Two fundamental cellular processes during breast cancer metastasis are intravasation (movement of cells into the bloodstream) and extravasation (movement of cells from the bloodstream into the tissue). The mechanisms behind breast cancer cell intravasation and extravasation remain an undeciphered question, as animal studies face tremendous difficulties due to complex cellular interactions. Therefore, establishing an external vascularized system would allow us to continuously monitor cellular movement and shed light on this enigmatic process. Luo et al. 2019 journal article highlighted the importance of two proteins, DAAM1 and DAAM2, in cell motility. Luo showed that the downregulation of DAAM2 results in no cellular movements, and DAAM1 inhibits DAAM2-promoted cell motility. My underlying hypothesis is that loss of DAAM1 will promote intravasation and intravasation while loss of DAAM2 will hinder them. To test this hypothesis, I will investigate the capability of two breast cancer cell lines (one metastatic and one benign) to undergo intravasation and extravasation using an external vascularized system. I will first establish the malignant and benign vascularized breast cancer systems. And then perform loss of function (CRISPR) and overexpression screens (CRISPRa) in benign breast cancer cells that have undergone intravasation in these systems using FACS sorting, followed by next-generation sequencing of the guide RNA (which indicated gene deletion/overexpression).
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Guo, Yaxin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~